Metabolic syndrome is not a single disease but a cluster of interlocking disorders — central obesity, elevated triglycerides, reduced high-density lipoprotein cholesterol, hypertension, and impaired fasting glucose — that together act as a powerful predictor of type 2 diabetes and cardiovascular disease. Its pathophysiology involves insulin resistance, chronic low-grade inflammation, oxidative stress, and, increasingly recognized, dysbiosis of the intestinal microbiota. Gut microbes and their metabolites, particularly short-chain fatty acids, act as signaling molecules that regulate host energy metabolism, immune function, and endocrine signaling. When this microbial ecosystem falls out of balance, the metabolic consequences can be profound. Probiotics — live microorganisms conferring a health benefit — and synbiotics, which combine live microbes with selectively utilized substrates, have emerged as interventions targeting this intestinal microecology directly.

Yet published meta-analyses of probiotic effects on metabolic syndrome have produced inconsistent findings, and most have focused almost exclusively on human randomized controlled trials, ignoring the mechanistic bridge that animal models provide. No previous study had integrated animal and clinical trial results to evaluate their consistency, differences, or interspecies translational value. The new analysis, led by Chunxing Li and Zhao Ren, addressed this gap by systematically searching PubMed, Embase, the Cochrane Central Register of Controlled Trials, CNKI, and Wanfang Data from database inception to June 10, 2025. The team included only pharmaceutical preparations — capsules, tablets, liquid formulations — with clearly defined dosages, strictly excluding dietary sources such as yogurt, kefir, and milk to reduce confounding from food matrix components like viable bacteria fluctuations, sugar, and fat interference.

The final synthesis drew on 35 studies: 12 clinical trials enrolling 696 patients with metabolic syndrome and 23 animal studies using rodent models, most commonly mice and rats fed high-fat diets. All outcome values reported in different units were standardized to a single common metric before pooling — blood glucose and lipid concentrations converted to milligrams per deciliter, serum insulin to picomoles per liter, free fatty acids to micromoles per liter. Meta-analyses were performed using Stata 15.0 with the DerSimonian-Laird random-effects model combined with the inverse variance method, calculating pooled mean differences and 95 percent confidence intervals. Sensitivity analyses, in which one study was omitted at a time, assessed result stability, while funnel plots and Egger’s test evaluated publication bias when ten or more studies were available.

The results in animal models were striking. Probiotic and synbiotic interventions significantly reduced fasting plasma glucose by a pooled 41.05 milligrams per deciliter (95 percent CI: −46.50 to −35.60, p < 0.001) and hemoglobin A1c by 1.17 percentage points (95 percent CI: −1.50 to −0.84). Body weight fell by a pooled 13.27 grams (95 percent CI: −18.66 to −7.88), triglycerides by 51.38 milligrams per deciliter, total cholesterol by 36.66 milligrams per deciliter, and low-density lipoprotein cholesterol by 18.86 milligrams per deciliter. High-density lipoprotein cholesterol rose by 10.03 milligrams per deciliter. Beyond these classical metabolic parameters, the interventions significantly reduced interleukin-6 by 15.07 picograms per milliliter, leptin by 20.95 nanograms per milliliter, and free fatty acids by 130.36 micromoles per liter, alongside significant improvements in liver function indicators including alanine aminotransferase and aspartate aminotransferase.

In human patients, the picture was more nuanced. Changes in fasting plasma glucose were non-significant, with a pooled mean difference of −8.76 milligrams per deciliter (95 percent CI: −18.29 to 0.77, p = 0.07). However, significant improvements were observed for body weight, which fell by a pooled 1.06 kilograms (95 percent CI: −1.70 to −0.42), and waist circumference, which decreased by 2.12 centimeters (95 percent CI: −3.70 to −0.55). The lipid profile showed consistent benefits: triglycerides dropped by 20.51 milligrams per deciliter, total cholesterol by 12.09 milligrams per deciliter, low-density lipoprotein cholesterol by 10.56 milligrams per deciliter, and high-density lipoprotein cholesterol rose by 1.97 milligrams per deciliter. Notably, hemoglobin A1c — a marker of average blood glucose over roughly three months — was significantly reduced by 0.08 percentage points (95 percent CI: −0.15 to −0.01, p = 0.03), even though fasting glucose itself was not.

This divergence between fasting glucose and hemoglobin A1c is one of the study’s most intriguing findings. Hemoglobin A1c reflects cumulative glycemic exposure over weeks to months, whereas fasting plasma glucose captures a single timepoint and is highly sensitive to day-to-day variation, recent meals, and concurrent medications such as metformin or statins that many patients continue taking. The authors suggest that probiotics may be exerting subtle but cumulative effects on long-term glycemic control that a single fasting measurement cannot detect. In animal models, where diets are rigorously controlled and baseline metabolic pathology is severe yet homogeneous, the true treatment effect is maximized — which may partly explain why fasting glucose reductions were so much larger in mice than in humans following uncontrolled outpatient diets.

The mechanistic biomarker analysis provides quantitative support for the metabolic endotoxemia hypothesis. In animal models, the interventions significantly reduced lipopolysaccharide — a component of Gram-negative bacterial cell walls that translocates into circulation when intestinal barrier function is impaired — by a pooled 55.23 units. Reduced LPS levels indicate restoration of intestinal barrier function, which is generally regarded as the initial target of probiotic intervention. Concurrent reductions in tumor necrosis factor-alpha and interleukin-6 suggest inhibition of the JNK and IKKβ/NF-κB inflammatory signaling pathways, which directly contributes to the restoration of insulin signaling. The decrease in interleukin-1beta implies suppressed activation of the NLRP3 inflammasome, further alleviating inflammatory cascades. Decreased leptin and elevated adiponectin reflect attenuation of lipotoxicity and improved adipose tissue inflammation, potentially mediated through regulation of AMPK-dependent metabolic pathways.

Subgroup analyses revealed that intervention efficacy may be influenced by age, baseline body mass index, probiotic dosage, and trial duration. Benefits were more pronounced in patients under 50 years and in those with a baseline BMI of 30 kilograms per square meter or greater, where the absolute reduction in fasting glucose was approximately six times that observed in the overweight subgroup. In animal models, the high-dose group — exceeding 10^9 colony-forming units daily — showed significant improvements in insulin resistance, interleukin-6, interleukin-1beta, and tumor necrosis factor-alpha, while the low-dose group did not, though the authors caution that the small sample size of the low-dose subgroup may have limited statistical power. All clinical trials included doses of at least 10^7 colony-forming units, generally exceeding the effective concentration threshold, which may explain why no clear dose-dependent difference emerged for glucose metabolism indicators.

Sensitivity analyses confirmed result stability for most outcomes, with low risk of publication bias in the clinical trials — all Egger’s test p-values exceeded 0.05 and funnel plots were symmetrical. In animal studies, some indicators showed potential publication bias, though the authors attribute funnel plot asymmetry most likely to genuine between-study heterogeneity rather than selective reporting. The team acknowledges substantial heterogeneity driven by differences in rodent strains, high-fat diet formulations, probiotic strains, dosages ranging from 10^7 to 10^11 colony-forming units, and intervention durations from 4 to 28 weeks. Most human trials used multi-strain formulations with distinct strain combinations and proportions, precluding meaningful subgroup analyses stratified by strain type. The authors conclude that probiotic and synbiotic supplementation represents a promising adjunctive strategy for managing metabolic syndrome, but that larger-sample, rigorous randomized controlled trials are required to define the optimal intervention regimen before widespread clinical application.

Subject of Research: Integrating preclinical and clinical evidence: a meta-analysis of probiotic/synbiotic interventions on metabolic syndrome

Article Title: Integrating preclinical and clinical evidence: a meta-analysis of probiotic/synbiotic interventions on metabolic syndrome

Article References: Li, C., Li, X., Li, J., Shi, Y., Sun, L., Yang, Q., & Ren, Z. (2026). Integrating preclinical and clinical evidence: a meta-analysis of probiotic/synbiotic interventions on metabolic syndrome. Frontiers in Microbiology, 17, Article 1995383. https://doi.org/10.3389/fmicb.2026.1995383

Image Credits: AI Generated

DOI: 10.3389/fmicb.2026.1995383

Keywords: Integrating, preclinical, clinical, evidence, meta-analysis, probiotic, synbiotic, interventions, metabolic, syndrome, scientific research